Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Feb;7(2):e1918.
doi: 10.1002/cnr2.1918. Epub 2023 Dec 11.

A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer

Rui Zou  1 , Yunhe Hao  1 , Yiyao Wang  2 , Feihu Yan  2 , Xu Peng  1 , Zepeng Huang  1 , Gang Chen  1
Affiliations
Multicenter Study

A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer

Rui Zou et al. Cancer Rep (Hoboken). 2024 Feb.

Abstract

Objectives: To analyze the clinical characteristics and influencing factors of hepatotoxicity in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death protein-1 (PD-1) inhibitors, and to provide a theoretical basis for the treatment of immune-related hepatotoxicity in patients with advanced HCC.

Methods: Retrospective analysis of clinical data of patients with advanced HCC from February 2021 to February 2023, in order to summarize and statistically analyze the influencing factors of immune-related liver adverse reactions.

Results: A total of 135 patients met the inclusion criteria, among whom 46 patients experienced varying degrees of immune-related liver adverse reactions, with an incidence rate of 34.1% (46/135). The time range of immune-related liver adverse reactions was 3-26 weeks, with a median time of 4 weeks. The age range of immune-related liver adverse reactions was 34-73 years, with a median age of 62 years. Statistical analysis of the influencing factors and liver adverse reactions showed that age, total bilirubin level, and Child-Pugh (C-P) grading were influencing factors for the occurrence of liver adverse reactions (p < .05), and among these three influencing factors, the proportion of males with ≥2 influencing factors was higher than that of females; liver function C-P B was an independent influencing factor for liver adverse reactions (p < .05).

Conclusion: For male patients over 60 years old, with bilirubin levels ≥51 μmol/L and liver function C-P B, close observation of the occurrence of immune-related adverse reactions during treatment is recommended.

Keywords: immune checkpoint inhibitor; immune-related adverse events; liver cancer immune therapy; liver toxicity.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Total bilirubin levels and Child–Pugh score affect the occurrence of liver adverse events.
FIGURE 2
FIGURE 2
Proportion analysis of age, total bilirubin levels, and C–P B level in male and female patients.
See this image and copyright information in PMC

References

    1. Rizzo A, Ricci AD, Brandi G. Adjuvant systemic treatment in hepatocellular carcinoma: tempted to do something, rather than nothing. Future Oncol. 2020;16(32):2587‐2589. doi:10.2217/fon-2020-0669 - DOI - PubMed
    1. Rizzo A, Ricci AD, Brandi G. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. Immunotherapy. 2021;13(8):637‐644. doi:10.2217/imt-2021-0026 - DOI - PubMed
    1. Santoni M, Rizzo A, Kucharz J, et al. Complete remissions following immunotherapy or immuno‐oncology combinations in cancer patients: the MOUSEION‐03 meta‐analysis. Cancer Immunol Immunother. 2023;72:1365‐1379. doi:10.1007/s00262-022-03349-4 - DOI - PMC - PubMed
    1. Chinese Clinical Oncology Society Immunotherapy Expert Committee, Chinese Clinical Oncology Society Antitumor Drug Safety Management Expert Committee , Jin L, et al. Chinese expert consensus on the construction of a multidisciplinary diagnosis and treatment collaborative group on toxicity related to Immunocheckpoint inhibitors. Chinese J Cancer Biother. 2022;29(11):6.
    1. Cooper MD, Takai T, Ravetch JV. Activating and Inhibitory Immunoglobulin‐like Receptors. Springer; 2001.

Publication types